Meta-analysis of steady-state pharmacokinetics of troglitazone and its metabolites

Journal of Clinical Pharmacology

Volumn 37, Issue 11, 1997, Pages 1038-1047

  Loi, Cho Ming ^a   Alvey, Christine W ^a   Randinitis, Edward J ^a   Abel, Robert ^a   Young, Malcolm A ^a   Koup, Jeffrey R ^b  

^a PFIZER INC   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TROGLITAZONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEALTH STATUS; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; PREDICTION; STEADY STATE;

EID: 0030734691     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04285.x     Document Type: Article

References (26)

1. Horikoshi H, Yoshioka T, Kawasaki T, Nakamura K, Matsunuma N, Yamaguchi K, et al: Troglitazone (CS-045), a new antidiabetic drug. Annu Rep Sankyo Res Lab 1994;46:l-57.
2. Lebovitz HE, Feinglos MN: Sulfonylurea drugs: mechanism of antidiabetic action and therapeutic usefulness. Diabetes Care 1978;1:189-198.
3. Bailey CJ, Turner RC: Drug Therapy: Metformin. NEngl JMed 1996;334:574-579.
4. Ciaraldi TP, Gilmore A, Olefsky JM, Goldberg M, Heidenreich KA: In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 1990;39: 1056-1002.
5. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H: Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988:37:1549-1558.
6. Iwamoto Y, Kuzuya T, Matsuda A, Awata T, Kumakura S, Inooka G, et al: Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 1991;14:1083-1086.
7. Sutter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM: Metabolic effects of new oral hypoglycémie agent CS-045 in NIDDM subjects. Diabetes Care 1992; 15:193-203.
8. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. NEngl] Med 1994;331:1188-1193.
9. Durnas C, Loi CM, Cusack BJ: Hepatic drug metabolism and aging. Clin Pharmacokinet 1990; 19:359-389.
10. Harris RZ, Benet LZ, Schwartz JB: Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995;50:222-239.
11. Bonate PL: Gender-related differences in xenobiotic metabolism. J Clin Pharmacol 1991;31:684-690.
12. Gwilt PR, Nahhas RR, Tracewell WG: The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet 1991;20:477-490.
13. Fleischmann R, Remmer H, Starz U: Induction of cytochrome P-448 iso-enzymes and related glucuronyltiansferases in the human liver by cigarette smoking. Eur J Clin Pharmacol 1986;30:475-480.
14. Dawson GW, Vestal RE: Smoking and drug metabolism. Pharmacol Ther 1982; 15:207-221.
15. Bertilsson L: Geographical/interracial differences in polymorphic drug oxidation: current state of knowledge of cytochromes P450 (GYP) 2D6 and 2C19. Clin Pharmacokinet 1995;29:192-209.
16. Murray M: P450 enzymes: inhibition mechanisms, genetic regulation and effects of liver disease. Clin Pharmacokinet 1992;23:132-146.
17. Weinshilboum R. Sulfotransferase pharmacogenetics. Pharmacol Ther 1990:45:93-107.
18. Jones AL, Roberts RC, Coughtrie MWH: The human phenolsulfotransferase polymorphism is determined by the level of expression of the enzyme protein. Biochem J 1993:296:287-290.
19. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979:28:1039-1057.
20. Miners JO, Attwood J, Birkett DJ: Influence of sex and oral contraceptive steroids on paracetamol metabolism. Br J Clin Pharmacol 1983:16:503-509.
21. Macdonald JI, Herman RJ, Verbeeck RK: Sex-difference and the effects of smoking and oral contraceptive steroids on the kinetics of diflunisal. Eur J Clin Pharmacol 1990:38:175-179.
22. Zysset T, Wietholtz H: Differential effect of Type I and Type II diabetes on antipyrine disposition in man. EUT J Clin Pharmacol 1988;34: 369-375.
23. Zysset T, Wietholtz H: Pharmacokinetics of caffeine in patients with decompensated Type I and Type II diabetes mellitus. Eur J Clin Pharmacol 1991:41:449-452.
24. Adithan C, Sriram G, Swaminathan RP, Krishnan M, Bapna JS, Chandrasekar S: Effect of type II diabetes mellitus on theophylline elimination. Int] Clin Pharmacol Ther Toxicol 1989;27:258-260.
25. Adithan C, Danda D, Swaminathan RP, Indhiresan J, Shashindran CH, Bapna JS, et al: Effect of diabetes mellitus on salivary paracetamol elimination. Clinical and Experimental Pharmacology and Physiology 1988; 15:465-471.
26. Loi CM, Vassos AB, Randinitis EJ, Koup JR, Sedman A: Pharmacokinetics of troglitazone in healthy subjects and in patients with Type II diabetes mellitus. Clin Pharmacol Ther 1997; 61:159.